Harold Tara Jr, MD
Assistant Professor of Clinical Medicine (Medical Oncology)
Research & Publications
Biography
News
Coauthors
Selected Publications
- Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.Bleickardt E, Argiris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biology & Therapy 2002, 1: 646-51. PMID: 12642688, DOI: 10.4161/cbt.314.
- Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer. Journal Of Immunotherapy (Hagerstown, Md. : 1997) 2008, 31: 569-76. PMID: 18528297, DOI: 10.1097/CJI.0b013e318177a4ba.
- Double-minute MYC amplification and deletion of MTAP, CDKN2A, CDKN2B, and ELAVL2 in an acute myeloid leukemia characterized by oligonucleotide-array comparative genomic hybridization.Kamath A, Tara H, Xiang B, Bajaj R, He W, Li P. Double-minute MYC amplification and deletion of MTAP, CDKN2A, CDKN2B, and ELAVL2 in an acute myeloid leukemia characterized by oligonucleotide-array comparative genomic hybridization. Cancer Genetics And Cytogenetics 2008, 183: 117-20. PMID: 18503831, DOI: 10.1016/j.cancergencyto.2008.02.011.
- Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.Chiang AC, Lake J, Sinanis N, Brandt D, Kanowitz J, Kidwai W, Kortmansky J, LaSala J, Orell J, Sabbath K, Tara H, Engelking C, Shomsky L, Fradkin M, Adelson K, Uscinski K, Vest K, Lyons C, Lemay A, Lopman A, Fuchs CS, Lilenbaum R. Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction. Journal Of Oncology Practice / American Society Of Clinical Oncology 2018, 14: e823-e833. PMID: 30537462, DOI: 10.1200/JOP.18.00419.